Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|September 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 9
- Volume 7
- Issue 9
HHS Readying Tobacco Documents for Website Debut
WASHINGTON--More of those long-secret tobacco industry documents that have come to light as the result of recent lawsuits will be coming to a website near you. President Clinton has ordered the Department of Health and Human Services (HHS) to take the steps necessary for making the documents more accessible to the public.
Advertisement
WASHINGTON--More of those long-secret tobacco industry documents that have come to light as the result of recent lawsuits will be coming to a website near you. President Clinton has ordered the Department of Health and Human Services (HHS) to take the steps necessary for making the documents more accessible to the public.
He also ordered the Justice Department to file a brief supporting the State of Minnesotas efforts to win the public release of a comprehensive index to tobacco company documents created by the industry for use during the states lawsuit against Big Tobacco.
HHS will prepare a plan for reviewing the documents and making them available in an index or digest form that people can search easily and that will be widely disseminated.
Articles in this issue
about 28 years ago
NCI Readies Its Cancer Genetics Network for Collaborative Studiesabout 28 years ago
Payer Relationships Key to Transplant Revenuesabout 28 years ago
Taking Family Cancer History May Release Emotionsabout 28 years ago
Ovarian Cortical Tissue Is Cryopreserved for Future Fertilityabout 28 years ago
Advice Offered for Daughters of Women With Breast Cancerabout 28 years ago
WHO to List Exchange Programs in Cancer Edabout 28 years ago
Women’s Groups Ask Congress for Global Tobacco Controlsabout 28 years ago
Brain Tumor Patients Urged to ‘Seize Control’ of Their Seizuresabout 28 years ago
UCSF Breaks Ground for Its New Clinical Cancer BuildingAdvertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5